Format

Send to

Choose Destination
J Allergy Clin Immunol. 2014 Mar;133(3):921-3. doi: 10.1016/j.jaci.2013.11.026. Epub 2014 Jan 10.

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

Author information

1
Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
2
Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom.
3
Respiratory Therapeutic Area Unit, R&D, GlaxoSmithKline, Research Triangle Park, NC.
4
Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Headington, Oxford, United Kingdom. Electronic address: ian.pavord@ndm.ox.ac.uk.
PMID:
24418480
DOI:
10.1016/j.jaci.2013.11.026
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center